0001104659-14-082018.txt : 20141119 0001104659-14-082018.hdr.sgml : 20141119 20141119153442 ACCESSION NUMBER: 0001104659-14-082018 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141117 FILED AS OF DATE: 20141119 DATE AS OF CHANGE: 20141119 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000890465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870439579 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: (908) 450-5300 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rogus Joseph J CENTRAL INDEX KEY: 0001299691 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23272 FILM NUMBER: 141234943 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE STREET 2: 3RD FLOOR CITY: BEDMINSTER STATE: NJ ZIP: 07921 4 1 a4.xml 4 X0306 4 2014-11-17 0 0000890465 NPS PHARMACEUTICALS INC NPSP 0001299691 Rogus Joseph J 550 HILLS DRIVE BEDMINSTER NJ 07921 0 1 0 0 SVP, Gbl Technical Operations Common Stock 2014-11-17 4 M 0 26782 3.34 A 46933 D Common Stock 2014-11-17 4 S 0 26782 30.003 D 20151 D Employee Stock Options (right to buy) 3.34 2014-11-17 4 M 0 26782 0 D 2020-02-19 Common Stock 26782 85343 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.18, inclusive. The reporting person undertakes to provide to NPS Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. On February 19, 2010, the reporting person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. As of the date of this filing, the performance criteria and the time-based criteria for 112,125 of these options has been satisfied. These options vested and became exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant. /s/ Joseph R. Rogus, by Jill Thompson as attorney in fact 2014-11-19